Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2025-04-09 Regulatory Filings
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Informacja o zakwalifikowaniu projektu Celon Pharma S.A. do objęcia dofinansowaniem w ramach Programu "Fundusze Europejskie dla Nowoczesnej Gospodarki" - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ("Zarząd") of Celon Pharma S.A. It details the receipt of information regarding a project qualification for funding ("Dofinansowanie") under a specific Polish government program ("Fundusze Europejskie dla Nowoczesnej Gospodarki"). The content focuses on the nature of the project (mRNA complex development), the total cost (121.2 million PLN), and the recommended funding amount (65.8 million PLN). Crucially, the last paragraph states: "O zawarciu umowy o Dofinansowanie Spółka poinformuje odrębnym raportem bieżącym" (The Company will inform about the conclusion of the Funding Agreement in a separate current report). This structure—announcing a significant event (funding award) but explicitly stating that the final contractual step will be announced later—is characteristic of a general regulatory disclosure or current report. Since the core subject is a significant financing/capital event (securing major grant funding), the most appropriate specific category is 'Capital/Financing Update' (CAP). It is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). It is a specific announcement about securing capital/funding.
2025-04-09 Polish
Pozytywne wyniki II fazy klinicznej CPL'36, inhibitora PDE10A w leczeniu dyskinez w chorobie Parkinsona - Content (EN)
Regulatory Filings Classification · 1% confidence The document reports positive Phase II clinical trial results for a drug (CPL'36) in treating Dyskinesia in Parkinson's disease. It details the study design (multinational, randomized, placebo-controlled), primary and secondary endpoints (UDysRS scores), statistical significance (p-values), safety data (adverse events), and concludes that the results are a 'breakthrough milestone'. This content is a direct announcement of significant operational/scientific results, not a general regulatory filing, a management change, or a dividend notice. It is too detailed for a simple Earnings Release (ER) which usually focuses on financial performance. Since there is no specific category for clinical trial results, and it is a major, material announcement, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure under MAR (Market Abuse Regulation, referenced by 'Legal basis Art. 17 section 1 MAR'). Given the options, RNS is the most appropriate fallback for material, non-financial operational news.
2025-03-04 English
Pozytywne wyniki II fazy klinicznej CPL'36, inhibitora PDE10A w leczeniu dyskinez w chorobie Parkinsona
Regulatory Filings Classification · 1% confidence The document reports positive top-line results from a Phase II clinical trial for a drug (CPL'36) treating Dyskinesia in Parkinson's disease. It details the study design (multinational, randomized, placebo-controlled), primary and secondary endpoints (UDysRS scores), statistical significance (p-values), and safety/adverse events. This content is a direct announcement of significant clinical trial data, which is typically released as an Earnings Release (ER) if tied to a reporting period, or more generally as a Regulatory Filing (RNS) if it's a specific, material, non-periodic announcement. Given the context of reporting specific, material, non-periodic clinical trial results, and the reference to 'Legal basis Art. 17 section 1 MAR - confidential information' (implying a market disclosure requirement), this fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if the company uses ERs for this purpose. Since it is not a full financial report (10-K, IR) or a presentation (IP), and it's a specific material event disclosure, RNS is the most appropriate general regulatory category for material, non-standard announcements. However, in many regulatory frameworks, the announcement of positive clinical trial results, especially when they are considered a 'breakthrough milestone,' is often categorized as a specific type of material event disclosure. Since there is no specific 'Clinical Trial Result' code, and it is a direct announcement of results rather than a link to a report (ruling out RPA), RNS serves as the best fit for a mandatory, material regulatory disclosure that isn't a standard periodic report.
2025-03-04 English
Pozytywne wyniki II fazy klinicznej CPL'36, inhibitora PDE10A w leczeniu dyskinez w chorobie Parkinsona - Content (PL)
Regulatory Filings Classification · 1% confidence The document reports the positive results of a Phase II clinical trial for a drug (CPL'36) in treating dyskinesia in Parkinson's disease patients. It details the study design (randomized, placebo-controlled), primary and secondary endpoints (UDysRS scale improvement), statistical significance (p<0.001), tolerability, and adverse events. This type of detailed announcement regarding clinical trial outcomes, especially when it's an update referencing a previous report (Raport bieżący 17/2024), strongly suggests a regulatory disclosure concerning the company's core operations and pipeline progress. Since it is a detailed report of clinical findings rather than a general earnings summary (ER) or a management discussion (MDA), and it is not a full annual/interim report (10-K/IR), it fits best under the general category for significant regulatory announcements that aren't covered by other specific codes. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a specific, material regulatory update that doesn't fit the financial report categories (10-K, IR, ER) or management/governance categories. It is not a Call Transcript (CT), Investor Presentation (IP), or a Legal Report (LTR).
2025-03-04 Polish
Pozytywne wyniki II fazy klinicznej CPL'36, inhibitora PDE10A w leczeniu dyskinez w chorobie Parkinsona
Regulatory Filings Classification · 1% confidence The document text is a formal announcement from Celon Pharma S.A. regarding the positive results of a Phase II clinical trial for their drug CPL'36 in treating dyskinesia in Parkinson's disease patients. It details the study design (randomized, placebo-controlled), primary and secondary endpoints (UDysRS scale improvements), statistical significance (p-values), tolerability, and adverse events. This content is characteristic of a significant clinical development update, which falls under the scope of general regulatory announcements or investor information, but specifically relates to the progress of a drug candidate. Since it is a detailed report of clinical trial outcomes, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but given the narrative format detailing trial results, RNS serves as the most appropriate general category for such specific, material, non-periodic disclosures that aren't standard financial reports (10-K, IR, ER). Given the options, and that it is a material update on drug development, RNS (Regulatory Filings) is the best fit as a catch-all for significant, non-standard disclosures, although it contains elements of an Investor Presentation. However, since it is a direct report of trial data, RNS is chosen as the most encompassing regulatory disclosure type here.
2025-03-04 Polish
Podjęcie decyzji o zmianie struktury organizacyjnej Emitenta - Content (EN)
Management Reports Classification · 1% confidence The document announces a significant internal organizational restructuring involving the establishment of three new organizational units (Shared Services Centre, Generic Business, and Innovation Business) and explicitly states the plan to execute a demerger by separation in the next stage, where the Issuer will become a holding company. This action directly relates to changes in the company's structure, operations, and future capital/business organization. While it touches upon business structure, it is not a standard financial report (10-K, IR, ER) or a management change (MANG). It is a fundamental change in how the business is organized and how capital/assets might be separated, making 'Capital/Financing Update' (CAP) or 'Management Reports' (MDA) potential candidates. However, the core announcement is about the internal reorganization and the planned demerger structure, which is a significant corporate action affecting structure and potentially capital allocation. Given the options, this type of structural change announcement, especially one detailing a planned demerger, fits best under 'Capital/Financing Update' (CAP) as it fundamentally alters the corporate structure and future financing/operational setup, or potentially 'Management Reports' (MDA) if viewed as a strategic update. Since it details the creation of separate entities and a planned separation (demerger), which is a form of corporate restructuring often linked to financing/capital strategy, CAP is a strong fit. If it were purely strategic commentary without the demerger plan, MDA might fit better. Given the explicit mention of demerger, CAP is selected.
2025-02-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.